Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Old drug, new tricks: aspirin may boost colon cancer survival for patients with gene mutation

29 October 2012

By Purvi Shah

Appeared in BioNews 679

Regular use of aspirin may extend the lives of colon cancer patients whose tumour carries a specific gene mutation, scientists report.

The study, published in the New England Journal of Medicine, used data from 964 patients with colorectal cancer. Ninety-seven percent of those with the mutation in the PIK3CA gene who had also been taking aspirin were still alive five years after diagnosis. This was in comparison with a 74 percent survival rate among patients with the mutation who were not taking the drug. Conversely, aspirin did not impact survival rate for patients not possessing the gene mutation.

Between one in six and one in five colorectal tumours are thought to carry the PIK3CA mutation.

'For the first time, we have a genetic marker that can help doctors determine which colorectal cancers are likely to respond to a particular therapy', said senior author Dr Shuji Ognio of the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, USA.

Aspirin is already frequently prescribed for colorectal cancer patients but doctors cannot predict which patients might benefit. This study suggests that the survival benefit is limited to those patients whose tumours have the PIK3CA mutation.

If so, then a gene test done before beginning could enable more selective prescription so that patients who do not have the mutation would be spared the risks, which include gastrointestinal ulcers and stomach bleeding, of aspirin therapy.

Speaking to CNN, Dr Ernest Hawk, vice president for cancer prevention and population sciences at the MD Anderson Cancer Center in Houston, USA, who was not involved in the study, called the research 'very compelling'. CNN reports that Dr Hawk 'believes that testing patients for this particular genetic mutation should be completely doable, since most pathology labs today now have the ability to test the DNA of tumours'.

However more work would need to be done before aspirin could be ruled out as therapy for patients whose tumours do not carry the mutation.

'Although these data are exciting and intriguing, they need to considered as preliminary and will require validation in prospective studies, given the small number of patients included in this study', writes Dr Boris Pasche, director of haematology/oncology at the University of Alabama, USA, in an editorial accompanying the study.

Were the results to be echoed by larger studies, 'Aspirin [could] become one of the oldest drugs to be used as a 21st-century targeted therapy', Dr Pasche concludes.

SOURCES & REFERENCES
Bloomberg News | 25 October 2012
 
New England Journal of Medicine | 25 October 2012
 
Harvard Gazette (press release) | 25 October 2012
 
WebMD | 25 October 2012
 
CNN Health | 25 October 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

23 March 2015 - by Rhys Baker 
Whether or not aspirin reduces a person's risk of bowel cancer could all be down to their genetic make-up, according to a US study...
06 May 2014 - by James Brooks 
A genetic variant carried by one in three people raises the risk of bowel cancer for people who eat a lot of processed meat, a study has found...
24 March 2014 - by Daryl Ramai 
A stool-sample DNA test has detected 92 percent of colon cancers in a large clinical trial, compared to 74 percent picked up by the most commonly used non-invasive test...

23 July 2012 - by Dr Kimberley Bryon-Dodd 
The genetic mutations underlying colon and rectal cancer are so similar that these cancers should be classified as one disease, a study suggests. Researchers analysed over 200 tumour samples and also identified genes that could serve as targets for future drug treatments...
19 December 2011 - by Sarah Pritchard 
A gene known as deleted colorectal carcinoma (DCC) could safeguard against the development of the colorectal cancer by inducing a process called apoptosis, or cell death...
31 October 2011 - by Suzanne Elvidge 
Taking a daily aspirin has been recommended for people with a high risk of an inherited form of bowel cancer. Results published in The Lancet suggested the risk for those with Lynch syndrome could be cut by 63 percent...
28 September 2009 - by Dr Will Fletcher 
Scientists in the UK have found that a daily dose of aspirin may halve the chance of men with Lynch Syndrome developing colon cancer, one of the three most common cancers in developed countries. Lynch Syndrome is an inherited condition, which increases vulnerability to cancers of the colon, rectum, stomach, brain, liver, womb and elsewhere. Whilst the syndrome only accounts for five per cent of all colon cancer cases, the new findings are significant because men with the condition normally ha...
18 August 2008 - by Dr Rachael Panizzo 
Scientists have identified one of the leading genetic causes of inherited colorectal cancer, reported in the journal Science. Research teams at the Northwestern University Feinberg School of Medicine and the Human Cancer Genetics Program at Ohio State University found that abnormal activity of the transforming growth factor-beta...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation